Experienced in Tissue Biopsy

Dr. Nikolaos A. Trikalinos

Oncology
Washington University
1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Tissue Biopsy
Washington University
1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nikolaos Trikalinos is an Oncologist in Saint Louis, Missouri. Dr. Trikalinos is rated as an Experienced provider by MediFind in Tissue Biopsy. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreatic Cancer, Familial Colorectal Cancer, and Tissue Biopsy. Dr. Trikalinos is currently accepting new patients.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Tissue Biopsy.

Specialties
Oncology
Licenses
Internal Medicine in MO
Hospital Affiliations
Barnes-Jewish St Peters Hospital
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Christian Hospital Northeast
Memorial Hospital
Languages Spoken
English
French
German
Greek
Portuguese
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

WASHINGTON UNIVERSITY
1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial)
A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial)
Enrollment Status: Recruiting
Publish Date: October 27, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Etoposide, Mitotane
Study Phase: Phase 3
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
Cabozantinib in High Grade Neuroendocrine Neoplasms
Cabozantinib in High Grade Neuroendocrine Neoplasms
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Procedure, Drug
Study Drug: Cabozantinib
Study Phase: Phase 2
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug, Procedure
Study Drug: Olaparib
Study Phase: Phase 2
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Drug
Study Drug: Adavosertib
Study Phase: Phase 2
Non-Operative Management and Early Response Assessment in Rectal Cancer
Non-Operative Management and Early Response Assessment in Rectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 23, 2025
Intervention Type: Drug, Radiation
Study Phase: Not Applicable
Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Procedure, Device, Drug
Study Drug: Defactinib
Study Phase: Phase 2
A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug, Procedure
Study Drugs: BMS-813160, Nivolumab, Gemcitabine, Nab-paclitaxel
Study Phase: Phase 1/Phase 2
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2025
Intervention Type: Procedure, Drug
Study Drugs: Elimusertib, Irinotecan Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 1
Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)
Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)
Enrollment Status: Terminated
Publish Date: January 29, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Testing the Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Testing the Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Enrollment Status: Terminated
Publish Date: October 08, 2024
Intervention Type: Drug, Procedure
Study Drugs: CDX-301, CDX-1140
Study Phase: Phase 2
Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: June 25, 2024
Intervention Type: Genetic, Drug
Study Drugs: Irinotecan, Ramucirumab
Study Phase: Phase 2
Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Rivoceranib or Trifluridine/Tipiracil as Monotherapies and Rivoceranib and Trifluridine/Tipiracil as Combination Therapy in Subjects With Metastatic Colorectal Cancer
Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Rivoceranib or Trifluridine/Tipiracil as Monotherapies and Rivoceranib and Trifluridine/Tipiracil as Combination Therapy in Subjects With Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: May 02, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Savolitinib
Study Phase: Phase 2
A Pilot Study of PET/MR for Rectal Cancer Treatment Monitoring and Surveillance
A Pilot Study of PET/MR for Rectal Cancer Treatment Monitoring and Surveillance
Enrollment Status: Terminated
Publish Date: February 14, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Pilot Study of Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
A Pilot Study of Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
Enrollment Status: Completed
Publish Date: October 05, 2022
Intervention Type: Procedure, Drug
Study Drugs: 5-Fluorouracil, Leucovorin, Liposomal Irinotecan, Paricalcitol
Study Phase: Phase 1
Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Enrollment Status: Terminated
Publish Date: April 21, 2021
Intervention Type: Drug, Procedure
Study Phase: Phase 1
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum (NORMAL-R)
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum (NORMAL-R)
Enrollment Status: Completed
Publish Date: February 18, 2021
Intervention Type: Drug, Radiation
Study Phase: Phase 2
A Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
A Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Enrollment Status: Terminated
Publish Date: July 29, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 19 Less Clinical Trials

53 Total Publications

Theranostics in Lung Neuroendocrine Tumors.
Theranostics in Lung Neuroendocrine Tumors.
Journal: Seminars in nuclear medicine
Published: January 31, 2025
Similar Doctors
Experienced in Tissue Biopsy
Dr. Alice Y. Zhou
Oncology
Experienced in Tissue Biopsy
Dr. Alice Y. Zhou
Oncology

Washington University

10 Barnes W Dr, 200 Asthma And Allergy Cente, 
St Louis, MO 
 (11.2 miles away)
314-996-8670
Experience:
10+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alice Zhou is an Oncologist in St Louis, Missouri. Dr. Zhou has been practicing medicine for over 10 years and is rated as an Experienced provider by MediFind in Tissue Biopsy. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Glioma, Gliomatosis Cerebri, and Tissue Biopsy. Dr. Zhou is currently accepting new patients.

Experienced in Tissue Biopsy
Dr. Omar Butt
Hematology | Oncology
Experienced in Tissue Biopsy
Dr. Omar Butt
Hematology | Oncology

Washington University

1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
 (0.1 miles away)
314-747-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Omar Butt is a Hematologist and an Oncologist in Saint Louis, Missouri. Dr. Butt is rated as a Distinguished provider by MediFind in Tissue Biopsy. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Tissue Biopsy.

Experienced in Tissue Biopsy
Dr. Mhd N. Rajeh
Hematology Oncology | Hematology | Oncology
Experienced in Tissue Biopsy
Dr. Mhd N. Rajeh
Hematology Oncology | Hematology | Oncology

Ssm Health Care Group

3685 Vista Ave, 
Saint Louis, MO 
 (1.5 miles away)
314-257-7000
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Mhd Rajeh is a Hematologist Oncology specialist and a Hematologist in Saint Louis, Missouri. Dr. Rajeh is rated as an Advanced provider by MediFind in Tissue Biopsy. His top areas of expertise are Multiple Myeloma, Hodgkin Lymphoma, Childhood Acute Myeloid Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Rajeh is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Trikalinos's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 81 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile